| Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose SJ Hadziyannis, H Sette Jr, TR Morgan, V Balan, M Diago, P Marcellin, ... Annals of internal medicine 140 (5), 346-355, 2004 | 3985 | 2004 |
| Telaprevir for retreatment of HCV infection S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts, R Focaccia, ... New England Journal of Medicine 364 (25), 2417-2428, 2011 | 2117 | 2011 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Journal of Medicine 370 (16), 1483-1493, 2014 | 1709 | 2014 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1503 | 2014 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1125 | 2016 |
| A placebo-controlled trial of obeticholic acid in primary biliary cholangitis F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ... New England Journal of Medicine 375 (7), 631-643, 2016 | 1122 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1087 | 2019 |
| Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and … E Lawitz, MS Sulkowski, R Ghalib, M Rodriguez-Torres, ZM Younossi, ... The Lancet 384 (9956), 1756-1765, 2014 | 1064 | 2014 |
| All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, ... Hepatology 61 (4), 1127-1135, 2015 | 891 | 2015 |
| Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial S Zeuzem, R Ghalib, KR Reddy, PJ Pockros, ZB Ari, Y Zhao, DD Brown, ... Annals of internal medicine 163 (1), 1-13, 2015 | 682 | 2015 |
| Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C KR Reddy, TL Wright, PJ Pockros, M Shiffman, G Everson, R Reindollar, ... Hepatology 33 (2), 433-438, 2001 | 531 | 2001 |
| Mutation analysis in hereditary hemochromatosis E Beutler, T Gelbart, C West, P Lee, M Adams, R Blackstone, P Pockros, ... Blood Cells, Molecules, and Diseases 22 (2), 187-194, 1996 | 510 | 1996 |
| Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study NH Afdhal, DT Dieterich, PJ Pockros, ER Schiff, ML Shiffman, ... Gastroenterology 126 (5), 1302-1311, 2004 | 431 | 2004 |
| Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels S Zeuzem, M Diago, E Gane, KR Reddy, P Pockros, D Prati, M Shiffman, ... Gastroenterology 127 (6), 1724-1732, 2004 | 356 | 2004 |
| Racial differences in responses to therapy with interferon in chronic hepatitis C KR Reddy, JH Hoofnagle, MJ Tong, WM Lee, P Pockros, EJ Heathcote, ... Hepatology 30 (3), 787-793, 1999 | 349 | 1999 |
| Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response NA Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, ... Gastroenterology 151 (6), 1131-1140. e5, 2016 | 262 | 2016 |
| Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies PJ Pockros, D Guyader, H Patton, MJ Tong, T Wright, JG McHutchison, ... Journal of hepatology 47 (2), 174-182, 2007 | 246 | 2007 |
| Risks of a range of alcohol intake on hepatitis C‐related fibrosis A Monto, K Patel, A Bostrom, S Pianko, P Pockros, JG McHutchison, ... Hepatology 39 (3), 826-834, 2004 | 231 | 2004 |
| Oral IDN‐6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C PJ Pockros, ER Schiff, ML Shiffman, JG McHutchison, RG Gish, NH Afdhal, ... Hepatology 46 (2), 324-329, 2007 | 230 | 2007 |
| Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection MS Sulkowski, HE Vargas, AM Di Bisceglie, A Kuo, KR Reddy, JK Lim, ... Gastroenterology 150 (2), 419-429, 2016 | 219 | 2016 |
K. Rajender ReddyUniversity of Pennsylvania在 uphs.upenn.edu 的电子邮件经过验证
